IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death. by Legendre, Christophe
IRX-2, a novel immunotherapeutic, protects human T
cells from tumor-induced cell death.
Christophe Legendre
To cite this version:
Christophe Legendre. IRX-2, a novel immunotherapeutic, protects human T cells from tumor-




Submitted on 20 Nov 2013
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Introduction
h e results of kidney transplantation have improved 
dramatically over the past 20  years  – although much 
progress has been made with regard to short-term results 
(1-year patient and graft survival), the attrition rate 
afterwards has changed minimally if at all [1]. In the 
meantime, immuno suppression became rather homo ge-
neous combining a calcineurin inhibitor (mostly 
tacrolimus), an inosine-5’-monphosphate dehydrogenase 
inhibitor, low-dose or no steroids and induction with 
either basiliximab (low-immunological risk patients) or 
h ymoglobulin® (high immunological risk patients; 
Genzyme, Paris, France) [2,3]. h e validity of this choice 
was further consolidated by publi cation of the Symphony 
study [4]. However, although the anti-rejection eﬃ  cacy of 
this immunosuppression is well known, its numerous 
side eﬀ ects (diabetes mellitus, nephrotoxicity, diarrhea, 
tremor, hypertension, and so forth) are also common! In 
particular, the responsibility of calcineurin inhibitor-
induced nephrotoxicity in chronic allograft dysfunction 
is currently less obvious while under immuno suppres-
sion-induced chronic antibody-mediated rejection is 
becom ing the leading cause of graft loss [5,6]. h ere is 
therefore a need for new immunosuppressive drugs that 
would display at least the same eﬃ  cacy (and hopefully 
greater eﬃ  cacy in high immunological risk patients) but 
a signiﬁ cantly more acceptable long-term safety proﬁ le. 
In this review we will focus on JAK3 inhibition, a 
potentially very promising new drug category [7,8].
JAK3 inhibition
h e Janus kinases (JAKs) are a family of four cytoplasmic 
tyrosine kinases that participate in the signaling of 
members of the cytokine receptor common gamma-
chain family. h e JAKs were initially named ‘just another 
kinase 1 and 2’ (since they were just two of a large 
number of discoveries in a PCR-based screen of kinases) 
but were ultimately named ‘Janus kinases’ [9]. h e name 
was taken from the two-faced Roman god of doorways, 
beginnings, change and transition, Janus, because the 
JAKs possess two almost identical phosphate-transferring 
domains. One domain exhibits the kinase activity, while 
the other negatively regulates the kinase activity of the 
ﬁ rst.
Schematically, there are four JAKs: JAK1, JAK2, JAK3 
and tyrosine kinase 2. h e activation of JAK occurs by a 
ligand–receptor interaction that results in signaling 
through the phosphorylation of cytokine receptors and 
the creation of docking sites for signaling proteins known 
as signal transducers and activators of transcription 
(STATs). JAKs catalyze STAT phosphorylation, which 
facilitates STAT dimerization and nuclear transport. h e 
end result is the regulation of gene expression and trans-
cription (Figure  1). h e JAK/STAT pathway is a signal-
trans duction pathway resulting in lymphocyte cell cycle 
propagation and subsequent cell proliferation.
More speciﬁ cally, JAK3, has a restrictive tissue distri-
bution on hematopoietic cells and is associated only with 
the common gamma-chain. Indeed, genetic absence or 
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mutation in either the common gamma-chain or JAK3 
produces defects in lymphoid development leading to a 
severe combined immunodeﬁ ciency syndrome pheno-
type [8,10], characterized by the absence of T cells and 
natural killer cells and the maintenance of normal 
numbers of poorly functional B cells (T–B+NK– SCID).
h is property together with the nonredundancy of the 
JAK/STAT pathway would therefore be important features 
of an eﬃ  cient novel immunosuppression based on JAK3 
inhibition.
CP-690,550 (later named tazocitinib and ﬁ nally 
tofacitinib) is an orally administered pyrrolo-pyrimidine 
JAK3 inhibitor [11,12] with a low inhibitory potency for 
JAK1 and JAK2 (thus avoiding bone marrow toxicity and 
especially anemia). Although CP-690,550 has been 
studied in various autoimmune disorders (psoriasis, 
Crohn’s disease, ulcerative colitis, rheumatoid arthritis, 
and so forth), we will focus on its indication in kidney 
transplantation ﬁ rstly in animal models and then in 
human transplantation.
Animal studies with CP-690,550
Murine model
h e in vivo eﬃ  cacy of CP-690,550 was ﬁ rst studied in a 
murine model of heterotopic heart transplantation [11]. 
Animals treated with vehicle alone rejected their 
allografts within 12  days. In contrast, dosing with CP-
690,550 resulted in a dose-dependent increase in survival 
of transplanted hearts. Although the drug was adminis-
tered for only 28 days, the two higher dose groups had 
median survival times >60 days. h ese data indicated that 
CP-690,550 was able to suppress a robust in vivo allo-
geneic response.
Nonhuman primates
Kidney transplantations were performed between mixed 
leukocyte reaction-mismatched, ABO blood group-
matched cynomolgus monkeys [11,13]. Animals received 
either CP-690,550 (n = 18) at various levels of exposure 
or its vehicle (n = 3) and were killed at day 90 or earlier in 
cases of allograft rejection. h e mean survival time in 
animals treated with CP-690,550 was signiﬁ cantly longer 
than that in control animals (53 ± 7 days vs. 7 ± 1 days, 
P  <0.0003) and was positively correlated with drug 
exposure. Four treated animals were euthanized at 
90  days with a normal renal function and low-grade 
rejection on ﬁ nal pathology. Occurrence of rejection was 
signiﬁ cantly delayed in treated animals (46 ± 7 days from 
transplantation vs. 7  ±  1  days in controls, P   <0.0003). 
Persistent anemia, polyoma virus-like nephritis (n  =  2), 
and urinary calcium carbonate accretions (n  =  3) were 
seen in animals with high drug exposure. Natural killer 
cells and CD4+ and CD8+ T cells were signiﬁ cantly 
reduced in treated animals. Blood glucose, serum lipid 
levels, and arterial blood pressure were within normal 
range in treated animals, and no cancer was demon-
strated. h ese data conﬁ rmed the immunosuppressive 
potential of CP-690,550.
Moreover, the immunomodulatory eﬀ ects of CP-
690,550 were studied in vitro and in vivo in nonhuman 
primates [14]. Pharmacodynamic assessments of lympho-
cyte activation, function, proliferation and phenotype 
were performed in three settings: in vitro in whole blood 
isolated from untransplanted cynomolgus monkeys, in 
vivo in blood from untransplanted cynomolgus monkeys 
dosed with CP-690,550 for 8  days, and in vivo in blood 
from transplanted cynomolgus monkeys immuno sup-
pressed with CP-690,550. In vitro exposure to CP-
690,550 resulted in a signiﬁ cant reduction of IL-2-
enhanced IFNγ production by T  cells, T-cell surface 
expression of CD25 and CD71, and T-cell proliferative 
capacities. Similar results were observed in animals 
dosed with CP-690,550. In addition, transplanted animals 
displayed signiﬁ cant reduction of natural killer cell and 
T-cell numbers whereas CD8+ eﬀ ector memory T-cell 
populations were unaﬀ ected.
Finally, addition of CP-690,550 to mycophenolate 
mofetil (MMF) signiﬁ cantly improved allograft survival 
[15]. In the same model, monkeys were treated orally 
twice a day with CP-690,550 together with MMF or 
MMF alone and were killed at day  90 or earlier due to 
allograft rejection. h e mean survival time in animals 
treated with MMF alone was signiﬁ cantly extended in 
animals that concurrently received CP-690,550 (23 ± 1 days 
Figure 1. Cytokine signaling of Janus kinases. Binding of a 
cytokine to its receptor activates the associated Janus kinase (JAK), 
which then phosphorylates (P) the receptor and provides a docking 
site for signal transducers and activators of transcription (STATs). In 
turn, STATs become phosphorylated and translocate to the nucleus 
to regulate gene expression. From [8].
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vs. 59.5  ±  9.8  days, P  <0.02). Combination animals 
exposed to higher levels of CP-690,550 had a signiﬁ cantly 
better survival than animals that received less CP-
690,550 (75.2  ±  8.7  days vs. 33.3  ±  12.6  days, P  <0.02). 
Anemia and gastrointestinal intolerance was seen in 
combination therapy animals that otherwise did not 
show evidence of viral or bacterial infection besides signs 
consistent with subclinical pyelonephritis.
We concluded from these three studies that the 
potential of CP-690,550 (eﬃ  cacy and safety proﬁ le) was 
in favor of beginning clinical trials in humans.
Human studies with CP-690,550
Phase 1 trial
In a dose-escalation study, the safety and tolerability 
eﬀ ects on lymphocyte subsets, and pharmacokinetics of 
CP-690,550 when coadministered with MMF were ﬁ rstly 
assessed in stable renal allograft recipients [16]. Twenty-
eight patients were enrolled: six patients received 
CP-690,550 5 mg twice daily (BID), six patients received 
15  mg BID, 10  patients received 30  mg BID, and six 
patients received placebo. h e most frequent adverse 
events were infections and gastrointestinal symptoms 
(abdominal pain, diarrhea, dyspepsia, and vomiting). 
CP-690,550 15 mg BID and 30 mg BID were associated 
with a mean decrease in hemoglobin from baseline (11%), 
and a mean decrease in absolute natural killer cell counts 
(50%). CP-690,550 30 mg BID was also associated with a 
mean increase in absolute CD19+ B lymphocytes (130%). 
h ere were no changes in the number of neutrophils, 
total lymphocytes, platelets, or CD4+ or CD8+ T cells, 
clinical chemistry, vital signs, or electrocardiograms from 
the pretreatment baseline. Administration of CP-690,550 
without a concomitant calcineurin inhibitor resulted in 
CP-690,550 exposures consistent with previous studies in 
nontransplant subjects.
As part of this study, the eﬀ ect of CP-690,550 after 
29 days of 30 mg BID treatment was investigated at the 
cellular level in eight kidney transplant recipients by 
studying ex vivo phosphorylation of STAT5, the key 
substrate of JAK3 [17]. As determined by quantitative 
ﬂ uorescent western blotting, IL-2-induced phosphory-
lated STAT5 in YT cells was reduced in the presence of 
serum collected on day 29 compared with pretreatment 
baseline. When evaluated by phosphospeciﬁ c ﬂ ow cyto-
metry, CP-690,550 also reduced IL-2-induced phos-
phory lated STAT5 in CD3+, CD3+CD4+ and CD3+CD8+ 
patient blood subpopulations.
Finally, again as part of the initial study [16], blood 
samples were collected on day  1 (before ﬁ rst dose), 
day  15, day  29 (end of treatment), and day  57 [18]. 
Leukocyte counts remained stable, whereas a signiﬁ cant 
decrease in hemoglobin (8%) was documented. 
CP-690,550 treatment for 29 days resulted in statistically 
signiﬁ cant changes in the number of circulating CD19+ B 
cells (increased), CD3+CD16+CD56+ natural killer cells 
(decreased), and CD4+CD25bright T cells (decreased). On 
day 15 after CP-690,550 treatment, the number of B cells 
increased (100%) whereas those of natural killer cells and 
CD4+CD25bright T cells decreased (65% and 38%, respect-
ively) from the pretreatment baseline. However, the 
regulatory capacities of the residual CD4+CD25bright T 
cells remained unchanged. In addition, in the presence of 
CP-690,550, the IFNγ production capacity of peripheral 
blood mononuclear cells was reduced compared with the 
predose baseline.
Phase 2a trial
Subsequently, a randomized pilot study compared CP-
690,550 (15 mg BID and 30 mg BID, n = 20 in each group) 
with tacrolimus (n  =  21) in de novo kidney allograft 
recipients [19]. Patients also received an IL-2 receptor 
antagonist, MMF and corticosteroids. CP-690,550 doses 
were reduced after 6 months. Due to a high incidence of 
BK virus nephropathy in CP30 patients, MMF was 
discontinued in this group. h e 6-month biopsy-proven 
acute rejection rates were one out of 20, four out of 20 
and one out of 21 for the 15 mg BID CP-690,550, 30 mg 
BID CP-690,550 and tacrolimus groups, respectively. BK 
virus nephropathy developed in four out of 20 patients in 
the 30 mg BID CP-690,550 group. h e 6-month rates of 
cytomegalovirus disease were two out of 20, four out of 
20 and none out of 21 for the 15  mg BID CP-690,550, 
30  mg BID CP-690,550 and tacrolimus groups, respect-
ively. h e estimated glomerular ﬁ ltration rate was 
>70  ml/minute at 6 and 12  months (all groups). In the 
CP-690,550 arms, there were modest lipid elevations and 
a trend toward more frequent anemia and neutropenia 
during the ﬁ rst 6  months. h ese data suggested that 
coadministration of 30  mg BID CP-690,550 with MMF 
was clearly associated with overimmunosuppression. At 
15 mg BID, the eﬃ  cacy/safety proﬁ le was comparable with 
that of the tacrolimus control group, except for a higher 
rate of viral infection (cycomegalovirus and BK virus).
In this study, the eﬀ ect of CP-690,550 on IL-2-
mediated JAK/STAT5 phosphorylation by 
CD4+CD25brightFoxP3+CD127−/low regulatory T cells (Tregs) 
and CD4+CD25– eﬀ ector T cells (Teﬀ s) was examined in 
kidney transplant patients [20]. Phospho speciﬁ c ﬂ ow 
cytometry was used to study the eﬀ ect of CP-690,550 on 
IL-2-induced intracellular STAT5 phos phory lation. IL-2-
induced phosphorylation of STAT5 was signiﬁ cantly 
higher for CD4+CD25bright Tregs than for CD4+CD25– 
Teﬀ s. In the presence of 100  ng/ml CP-690,550, a 
clinically relevant exposure, IL-2-induced phos phory-
lated STAT5 was partially inhibited in CD4+CD25bright 
Tregs but was almost completely blocked in Teﬀ s. h e 
IC50 was two or three times higher for Tregs than for 
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Teﬀ s. In the presence of CP-690,550, Tregs exhibited 
additional suppressive activities on the alloactivated 
proliferation of Teﬀ s. In addition, CD4+CD25bright Tregs 
from kidney trans plant patients receiving CP-690,550 
vigorously suppressed the proliferation of Teﬀ s.
CP-690,550 was therefore inhibiting Teﬀ  function but 
preserved the suppressive activity of CD4+CD25bright 
Tregs.
Phase 2b trial
In a Phase 2b, randomized, multicenter, partially blinded, 
parallel group study [21], 331 low to moderate risk de 
novo kidney transplant patients were randomized to a 
more intensive or less intensive regimen of tofacitinib 
(CP-690,550) or cyclosporine. All patients also received 
basiliximab induction, MMF and corticosteroids. Co-
primary noninferiority endpoints were incidence of the 
biopsy-proven acute rejection rate at month 6 or biopsy-
proven rejection meeting serum creatinine criteria at 
month 6 (serum creatinine increase ≥0.3 mg/dl and ≥20% 
from pre-rejection baseline) and measured glomerular 
ﬁ ltration rate at month 12.
Similar 6-month incidences of clinical biopsy-proven 
acute rejection (11%, 7% and 9%) were observed for the 
more intensive, less intensive and cyclosporine groups. 
Measured glomerular ﬁ ltration rates were higher at 
month 12 for the more intensive and less intensive groups 
versus the cyclosporine group (65  ml/minute, 65  ml/
minute vs. 54  ml/minute). Fewer patients in the more 
intensive or less intensive groups developed chronic 
allograft nephropathy at month  12 compared with 
cyclosporine patients (25%, 24% vs. 48%). Serious 
infections (especially cytomegalo virus and BK virus) 
developed in 45%, 37% and 25% of more intensive 
patients, less intensive patients and cyclo sporine patients, 
respectively.
Anemia, neutropenia and posttransplant lympho pro-
lifera tive disorder (four patients) occurred more 
frequently in more intensive and less intensive patients 
compared with cyclosporine patients. Tofacitinib was 
therefore equivalent to cyclosporine in preventing acute 
rejection, was associated with improved renal function 
and less chronic allograft histological injury, but 
developed serious side eﬀ ects at the doses evaluated with 
an exposure–response relationship. h is not un expect-
edly high incidence of infectious complications is 
probably due to the broad JAK3-inhibited gamma-chain-
dependent cytokines such as IL-2, IL-4, IL-7, IL-9, IL-15 
and IL-21 [22]. h is aﬀ ects natural killer cells (IL-15) and 
the memory T-cell compartment. Patients receiving this 
compound therefore probably mount a less eﬃ  cient 
primary antiviral response as well as a secondary one.
It would have been very interesting to try to keep the 
potent immunosuppressive eﬀ ect together with the 
absence of nephrotoxicity either by avoiding high drug 
exposure, which seemed to correlate with infectious 
complications, or by modifying the companion drug or 
its dosage.
Conclusion
Inhibiting JAK3 with tofacitinib was, and still is, clearly 
an attractive option in transplantation with a low 
incidence of rejection, no nephrotoxicity, and better 
histological preservation but a safety proﬁ le that was not 
ideal for low to moderate risk patients (more infections 
and cancers). Recently, following as yet unpublished data 
with a longer follow-up time, the development of 
tofacitinib had to be discontinued due mainly to a still 
higher incidence of infections in the treated group. As 
the number of high immunological risk patients is 
increasing steadily in most transplant center programs, it 
is unfortunate that this drug was not tested in such 
subgroups. Overall, this has been felt as a missed 
opportunity by the transplant community in need of new 
and better immuno sup pressive drugs.
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